FibroGen Announces Initiation of Phase 2b Studies of FG-4592, an Oral HIF ... - Business Wire (press release) PDF Print
Business Wire (press release)
FibroGen enrolled anemic Stage 5 CKD patients [end-stage renal disease (ESRD)] on hemodialysis therapy in a phase 2a dose-escalation study to evaluate the ability of these patients to maintain and/or to correct hemoglobin levels when converted from

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.